Novartis

Update in progress

NVS (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Novartis AG researches, develops, manufactures, distributes, and markets pharmaceutical medicines worldwide from Basel, Switzerland. It covers cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. Key therapies include Entresto, Cosentyx, Kisqali, Promacta/Revolade, Tafinlar+Mekinist, Jakavi, Tasigna, Xolair, Ilaris, Pluvicto, Sandostatin, Zolgensma, Lucentis, Leqvio, Lutathera, Scemblix, and others, with a licensing collaboration with Alnylam for Leqvio.

Company score

Sentiment: 0.36; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.06; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.65; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.85; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNYSE (NYQ)
LocationSwitzerland
Founded1996
Employees75,267
Websitewww.novartis.com

Identifiers

ISINUS66987V1098
FIGIBBG000LYF3S8
LEI5493007HIVTX6SY6XD66
CUSIP66987V109
CIK0001114448